Marinus J Blok

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6192978/publications.pdf

Version: 2024-02-01

25 papers	2,030 citations	394421 19 h-index	580821 25 g-index
25 all docs	25 docs citations	25 times ranked	4755 citing authors

#	Article	IF	Citations
1	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
2	Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. International Journal of Molecular Sciences, 2017, 18, 308.	4.1	353
3	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
4	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
5	Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2019, 177, 723-733.	2.5	111
6	Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Human Molecular Genetics, 2014, 23, 3666-3680.	2.9	96
7	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
8	Naturally occurringBRCA2alternative mRNA splicing events in clinically relevant samples. Journal of Medical Genetics, 2016, 53, 548-558.	3.2	69
9	NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Human Mutation, 2017, 38, 226-235.	2.5	55
10	The BRCA1 c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. Journal of Medical Genetics, 2018, 55, 15-20.	3.2	50
11	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
12	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
13	BRCA1 Circos: a visualisation resource for functional analysis of missense variants. Journal of Medical Genetics, 2015, 52, 224-230.	3.2	32
14	Dutch genome diagnostic laboratories accelerated and improved variant interpretation and increased accuracy by sharing data. Human Mutation, 2019, 40, 2230-2238.	2.5	32
15	Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing. Breast Cancer Research and Treatment, 2011, 129, 971-982.	2.5	29
16	Generation and initial characterization of novel tumour organoid models to study human pancreatic cancerâ€induced cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1509-1524.	7.3	29
17	Targeted RNAâ€seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. International Journal of Cancer, 2019, 145, 401-414.	5.1	27
18	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	2.5	24

#	Article	IF	Citations
19	Growth pattern in Kabuki syndrome with a KMT2D mutation. American Journal of Medical Genetics, Part A, 2016, 170, 3172-3179.	1.2	23
20	PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. European Journal of Human Genetics, 2013, 21, 1361-1368.	2.8	21
21	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	2.5	18
22	BRCA1 and BRCA2 5â€² noncoding region variants identified in breast cancer patients alter promoter activity and protein binding. Human Mutation, 2018, 39, 2025-2039.	2.5	15
23	Pathogenic neurofibromatosis type 1 (NF1) RNA splicing resolved by targeted RNAseq. Npj Genomic Medicine, 2021, 6, 95.	3.8	9
24	Prevalence of Germline Pathogenic Variants in Cancer Predisposing Genes in Czech and Belgian Pancreatic Cancer Patients. Cancers, 2021, 13, 4430.	3.7	8
25	Germ-line variants identified by next generation sequencing in a panel of estrogen and cancer associated genes correlate with poor clinical outcome in Lynch syndrome patients. Oncotarget, 2015, 6, 41108-41122.	1.8	5